Android app on Google Play

BioLineRx (BLRX) Closes BL-8040 In-License Agreement

January 16, 2013 7:14 AM EST Send to a Friend
Get Alerts BLRX Hot Sheet
Trade BLRX Now!
Join SI Premium – FREE
On September 4, 2012, BioLineRx Ltd. (Nasdaq: BLRX) entered into an agreement (the “Agreement”) with Biokine Therapeutics Ltd. to in-license the rights to BL-8040 for the treatment of acute myeloid leukemia, as well as other types of hematological cancer. The closing of the transaction was subject to formal approval of the Office of the Chief Scientist of Israel’s Ministry of Industry, Trade and Labor (the “OCS”). The approval of the OCS was obtained on January 14, 2013, and therefore the transaction has now closed and the Agreement has become effective according to its terms.




You May Also Be Interested In


Related Categories

Corporate News, FDA, Litigation

Add Your Comment